| abstract |
New enteric-coated pharmaceutical form for oral administration of an active ingredient in risedronate. It consists of a harmless and effective amount of a pharmaceutical composition composed of an active ingredient in risedronate and pharmaceutically acceptable excipients. These pharmaceutical forms prevent exposure of the active ingredient to risedronate to the epithelial and mucous tissues of the oral cavity, pharynx, esophagus and stomach, and can therefore protect these tissues from erosion, ulceration or similar irritation. Therefore, said pharmaceutical forms provide for the release into the lower intestine of humans or other mammals of a harmless and effective amount of an active ingredient in risedronate, as well as appreciable relief of esophagitis or esophageal irritation which are sometimes associated with oral administration of the active ingredients to risedronate. |